9 completed, 4 recruiting, 3 terminated, 3 unknown. 7 Phase 3, 6 Phase 4, 4 Phase 1, 2 Not applicable, 2 Phase 2.
Follow Rivaroxaban 10 MG: new trials by email Literature Review of Rivaroxaban 10 MG trials Research Report on Rivaroxaban 10 MG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy Rivaroxaban 10 MG, Placebo control - Venous Thromboembolism, Urologic Cancer | Phase 2 / Phase 3 | Recruiting | Ottawa Hospital Research Institute | 120 | 2024-11-04 | 2025-07-10 |
| RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing Rivaroxaban 10 MG, Low Heparin Molecular Weight - Venous Thromboembolism, Deep Vein Thrombosis | Phase 3 | Recruiting | University Hospital, Angers | 1424 | 2024-07-19 | 2026-06-25 |
| Rivaroxaban in Idiopathic Membranous Nephropathy Rivaroxaban 10 MG, Warfarin Sodium - Idiopathic Membranous Nephropathy | Phase 4 | Recruiting | Beijing Friendship Hospital | 134 | 2024-01-05 | 2026-02-11 |
| Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients Rivaroxaban 10 MG, Placebo - Glioma, Malignant | Not applicable | Unknown | Nanfang Hospital, Southern Medical University | 320 | 2023-11-01 | 2024-01-09 |
| Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty Rivaroxaban 10 MG - Venous Thromboembolism, Arthroplasty | Not applicable | Completed | Chiayi Christian Hospital | 150 | 2023-02-01 | 2026-04-24 |
| Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters Rivaroxaban 10 MG - Venous Thromboembolism, Cancer | Phase 3 | Recruiting | Ottawa Hospital Research Institute | 1828 | 2022-10-05 | 2025-07-09 |
| THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS) Rivaroxaban 10 MG, Placebo - Sickle Cell Disease, Central Venous Catheter Thrombosis | Phase 3 | Terminated | University Health Network, Toronto | 4 | 2022-06-07 | 2025-03-19 |
| Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in Colorectal Cancer Rivaroxaban 10 MG - Deep Venous Thrombosis, Colonic Cancer | Phase 4 | Unknown | Hospital do Servidor Publico Estadual | 68 | 2022-06-01 | 2022-03-31 |
| Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial Rivaroxaban 10 MG - Covid19, Venous Thromboembolism | Phase 3 | Completed | Science Valley Research Institute | 320 | 2020-10-16 | 2022-04-06 |
| COVID-19 Antithrombotic Rivaroxaban Evaluation Rivaroxaban 10 mg - COVID-19 | Phase 4 | Terminated | Hospital Alemão Oswaldo Cruz | 660 | 2020-09-29 | 2023-01-25 |
| Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines Rivaroxaban 10 MG - Upper Extremity Deep Vein Thrombosis, Central Venous Catheter Thrombosis | Phase 3 | Completed | Ottawa Hospital Research Institute | 105 | 2019-03-15 | 2024-07-05 |
| Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism Warfarin, Apixaban 2.5 MG, Rivaroxaban 10 MG - Venous Thromboembolism | Phase 4 | Terminated | Duke University | 44 | 2018-08-01 | 2019-12-13 |
| A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa Andexanet alfa (Gen 1 Process 2), Apixaban 5 MG, Rivaroxaban 20 MG - Bleeding | Phase 1 | Completed | Portola Pharmaceuticals | 153 | 2017-02-26 | 2023-08-08 |
| Rivaroxaban or Aspirin for Biological Aortic Prosthesis Rivaroxaban 10 MG, Aspirin - Aortic Stenosis, Aortic Regurgitation | Phase 4 | Unknown | Christian Torp-Pedersen | 1000 | 2017-01-01 | 2018-06-27 |
| Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients Rivaroxaban 10 MG, Rivaroxaban 20 MG, Low-molecular-weight heparin - Neoplasms | Phase 1 / Phase 2 | Completed | Capital Medical University | 74 | 2016-02-16 | 2019-04-16 |
| PK of Rivaroxaban in Bariatric Patients - Extension Rivaroxaban 10 mg - Prophylaxis of Venous Thromboembolism | Phase 1 | Completed | Insel Gruppe AG, University Hospital Bern | 13 | 2016-02-01 | 2017-04-11 |
| Rivaroxaban in Bariatric Surgery Rivaroxaban 10 mg - Prophylaxis of Venous Thromboembolism | Phase 1 | Completed | Insel Gruppe AG, University Hospital Bern | 13 | 2015-06-01 | 2016-01-08 |
| Dose-finding of Rivaroxaban in Hemodialysis Rivaroxaban 10 mg - Chronic Renal Failure | Phase 4 | Completed | AZ Sint-Jan AV | 18 | 2013-09-01 | 2015-01-14 |
| A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg - Atrial Fibrillation, Percutaneous Coronary Intervention | Phase 3 | Completed | Janssen Scientific Affairs, LLC | 2124 | 2013-05-10 | 2017-09-19 |
Venous Thromboembolism (8) · Neoplasms (3) · COVID-19 (2) · Upper Extremity Deep Vein Thrombosis (2) · Venous Thrombosis (2) · Anemia, Sickle Cell (1) · Aortic Valve Insufficiency (1) · Aortic Valve Stenosis (1) · Arrhythmias, Cardiac (1) · Atrial Fibrillation (1) · Colonic Neoplasms (1) · Dyskinesias (1) · Emergencies (1) · Glioma (1) · Glomerulonephritis, Membranous (1)
Ottawa Hospital Research Institute (3) · Insel Gruppe AG, University Hospital Bern (2) · AZ Sint-Jan AV (1) · Beijing Friendship Hospital (1) · Capital Medical University (1) · Chiayi Christian Hospital (1) · Christian Torp-Pedersen (1) · Duke University (1) · Hospital Alemão Oswaldo Cruz (1) · Hospital do Servidor Publico Estadual (1) · Janssen Scientific Affairs, LLC (1) · Nanfang Hospital, Southern Medical University (1) · Portola Pharmaceuticals (1) · Science Valley Research Institute (1) · University Health Network, Toronto (1)
Canada (5) · Brazil (4) · China (3) · United States (3) · Belgium (2) · Denmark (2) · France (2) · Switzerland (2) · Taiwan (2) · Argentina (1) · Australia (1) · Bulgaria (1) · Chile (1) · Czechia (1) · Germany (1)
An S De Vriese, MD, PhD (1) · Delphine Douillet, Doctor (1) · Dino Kroell, ME (1) · Dr. Marc Carrier (1) · Eduardo Ramacciotti, MD, Ph.D (1) · Guanglong Huang, M.D. (1) · Leandro Agati, PhD (1) · Luke T Lavallee, MDCM MSc FRCSC (1) · Rick T Ikesaka, MD (1) · Thomas Ortel, MD (1)
PMID 37591523, PMID 25819853, PMID 27881555, PMID 27959713, PMID 29550085, PMID 29943350, PMID 30015064, PMID 30704287, PMID 30903459, PMID 31535314, PMID 31707805, PMID 34027291, PMID 34480880, PMID 37018790, PMID 37223666, PMID 38171625, PMID 41249873, PMID 42767263
2016 (1), 2023 (1)